While these molecular signatures distinguish tumour aggressiveness, only age and certain cell cycle genes (CDK4, CDKN1B) achieved independent prognostic significance in multivariate models, underscoring the need for further validation of molecular risk markers. This evidence concerns the gene CDKN1B and neoplasm.